Online citations, reference lists, and bibliographies.
← Back to Search

‘The Same Old Story’: Thoughts On Authorized Doses Of Anticancer Drugs

F. Meriggi, A. Zaniboni
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Introduction Worldwide, tumours are currently one of the main causes of death with approximately 9.6 million deaths a year and an incidence of approximately 18.1 million new cases in 2018.1 Consequently, the prevention, diagnosis and treatment of cancer represent, more than ever before, goals towards which all international administrations are moving; however, the results are not always tangible and comforting. One of the causes of these total or partial failures has been identified as the absence of adequate nationwide awareness programmes regarding the lifestyles most likely to reduce the incidence of cancer, as well as a shortage of funding for research and for the distribution of the most innovative medicinal products to the whole population. On the other hand, cancer is a huge business opportunity for pharmaceutical companies around the world, even more now than in the past. A review by Hong and colleagues2 shows that in the United States between 2011 and 2016, spending on cancer drugs grew by over 50% (from US$26.8 to 42.1 billion). Although the introduction of immune checkpoint inhibitors has dramatically changed the treatment of a number of cancer types, they bring a host of new adverse effects to be managed and a further exponential increase in both direct and indirect costs. Researchers are exploring new strategies making it possible to deal in the years to come with what can be defined as an authentic politico-socio-economic emergency that is now well identified, also regarding the possibly over simplistic terminology such as the ‘financial toxicity’ of cancer treatments. The price, not merely in economic terms, that is likely to have to be paid is dramatic meaning that much of the world population, even in higher income countries, could be excluded from access to the most novel cancer treatments. One well consolidated, albeit far from decisive, pathway undertaken in an attempt to reduce costs is the authorization of biosimilars and generic medicines. Another option to be given careful attention is that of reconsidering (at equal efficacy) the authorized doses of certain medicinal products, especially those with higher costs, particularly when used on a large scale such as those indicated for the treatment of the most frequently terminal cancers.
This paper references
10.1200/JCO.2006.06.5391
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
S. Jones (2006)
10.1200/JCO.2006.06.8429
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
E. Van Cutsem (2006)
10.1016/S1470-2045(17)30422-9
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
M. Overman (2017)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1093/annonc/mdp573
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
A. Paccagnella (2010)
10.1200/JCO.1996.14.9.2590
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
H. Gurney (1996)
10.1056/NEJMOA1606774
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
10.1056/NEJMoa1504030
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
10.1200/JCO.2008.18.4028
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
S. Jones (2009)
10.1002/14651858.CD008792.pub2
Combination versus sequential single agent chemotherapy for metastatic breast cancer.
Rachel F Dear (2013)
10.1200/JCO.2007.14.9930
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
L. Saltz (2008)
10.1097/01.coc.0000037736.69148.F9
Retrospective Analysis of Safety and Efficacy of Low-Dose Docetaxel 60 mg/m2 in Advanced Non–Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy
Y. Nakamura (2003)
10.1056/NEJMoa1003825
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
E. Raymond (2011)
10.1200/JCO.2003.01.058
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
C. Smorenburg (2003)
10.1097/00000421-199104000-00004
A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer
A. Depierre (1991)
10.1200/JCO.1998.16.7.2297
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
M. Ratain (1998)
10.1200/JCO.2018.36.4_SUPPL.611
Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)–An ACCRU Network study.
T. Bekaii-Saab (2018)
10.1056/NEJMoa1014618
Abiraterone and increased survival in metastatic prostate cancer.
J. D. de Bono (2011)
10.1016/S0140-6736(15)01281-7
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
10.1056/NEJMoa1209096
Abiraterone in metastatic prostate cancer without previous chemotherapy.
C. Ryan (2013)
10.1200/JCO.2016.34.15_SUPPL.TPS3630
Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC).
T. Bekaii-Saab (2016)
Population pharmacokinetics of doxorubicin
G Freyer
10.1080/14737140.2017.1276830
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma
S. Bracarda (2017)
10.1038/bjc.2012.357
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
E. Chatelut (2012)
10.1200/JCO.1991.9.8.1480
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
M. Ratain (1991)
10.1200/JCO.2017.76.4381
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
R. Szmulewitz (2018)
10.1038/bjc.1998.556
What is the effect of adjusting epirubicin doses for body surface area?
N. Dobbs (1998)
10.1200/JCO.20.1.81
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
R. Mathijssen (2002)
10.1200/JCO.2009.26.9589
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C. Fong (2010)
Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
LB Saltz (2008)
10.1023/A:1010639201787
Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing
M. Sawyer (2004)
10.1136/bmj.k4930
Reporting harms more transparently in trials of cancer drugs
(2018)
10.1200/JCO.2010.28.5437
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
W. Eiermann (2011)
10.1016/S0140-6736(10)61389-X
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
J. Bono (2010)
10.1200/JOP.18.00069
Spending on Antineoplastic Agents in the United States, 2011 to 2016.
Samuel J Hong (2018)
10.1006/GYNO.2000.5921
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
M. Markman (2000)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325
E Van Cutsem (2006)
Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd (2000)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1159/000093005
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)
10.1093/annonc/mdv589
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
S. Bracarda (2016)
10.1056/NEJMoa1510665
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
10.1200/JCO.2002.09.002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
10.1200/JCO.2002.20.6.1434
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
M. Ratain (2002)
10.1056/NEJMoa1613683
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt (2017)
Advances in cancer
A Sparreboom (2009)
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group
E. Cutsem (2006)
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
10.1016/S0140-6736(17)31046-2
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
A. El-Khoueiry (2017)
10.1016/j.ejca.2019.08.010
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
M. Davidson (2019)
10.1200/JCO.1998.16.5.1948
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
J. Zalcberg (1998)
10.1056/NEJMOA070956
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
M. Posner (2007)
10.1200/JCO.2000.18.10.2095
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
F. Shepherd (2000)
10.1093/annonc/mdx235
Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
X. Zhao (2017)
10.1001/jamaoncol.2018.5877
Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual
D. Shepshelovich (2019)
10.1200/JCO.18.00045
Time Is Money: Optimizing the Scheduling of Nivolumab.
M. Ratain (2018)
10.1056/NEJMOA1611310
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
M. Mirza (2016)
10.1200/JCO.2007.12.0758
The value meal: how to save $1,700 per month or more on lapatinib.
M. Ratain (2007)
10.1200/JCO.2000.18.12.2354
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
F. Fossella (2000)
Firstand second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis
DA Goldstein (2015)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1056/NEJMoa1702900
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. James (2017)
10.1182/blood-2016-11-749556
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
C. Herbaux (2017)
10.1007/s10637-013-0055-4
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
L. Devriese (2013)
10.1007/978-1-62703-758-7_17
Sources of interindividual variability.
K. Thummel (2014)
Dosing of anticancer agents in adults
KD Eaton (2018)
10.1038/sj.bdj.2016.860
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
J. Radford (2016)
10.1159/000084823
High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer
J. Stemmler (2005)
10.1200/JCO.2007.15.4138
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
H. Hochster (2008)
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
W. Loos (2000)
10.1038/clpt.2008.259
Advances in Cancer Therapeutics
A. Sparreboom (2009)
10.1081/CNV-120014883
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
A. Perez (2002)
etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
(2000)
A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (every 4 weeks) dosing schedule across multiple tumor types. Presented at American Association for Cancer
X Zhao (2017)
10.1056/NEJMoa1709030
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber (2017)
10.1007/s002800051118
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
J. Cassidy (1999)
10.1056/NEJMOA065044
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
10.1016/S1470-2045(12)70537-5
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
P. Kellokumpu-Lehtinen (2013)
Abiraterone and increased survival in metastatic F Meriggi and A Zaniboni journals.sagepub.com/home/tam 7 prostate cancer
JS de Bono (2011)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1016/j.jtho.2017.07.005
ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
B. Cho (2017)
A phase II randomized study of lower dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC)
T S Bekaii-Saab (2018)
10.1093/jnci/djm287
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
P. Francis (2008)
10.1200/JCO.1994.12.2.360
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
T. Le Chevalier (1994)
10.1200/JCO.2016.72.1076
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
M. Eisenberger (2017)
10.1200/JCO.2001.19.17.3733
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
F. D. de Jongh (2001)
10.1093/JNCI/94.24.1883
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
S. Baker (2002)
10.1016/S0140-6736(12)61900-X
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A. Grothey (2013)
10.1093/ageing/afy079
Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis
V. Arciero (2018)
10.1158/1078-0432.CCR-14-2607
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
A. Patnaik (2015)
10.1056/NEJMoa1704174
Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer
K. Fizazi (2017)
10.1016/S0959-8049(97)00345-6
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
M. Etienne (1998)
10.1046/J.1365-2125.2000.00269.X
Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
G. Freyer (2000)
10.1016/S1470-2045(15)00083-2
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
10.1056/NEJMc1509660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
M. Valsecchi (2015)
10.1200/JCO.2014.58.4904
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
D. Goldstein (2015)
10.1056/NEJMOA071028
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
J. Vermorken (2007)
10.1016/S0959-8049(02)00151-X
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
A. Felici (2002)
10.1056/NEJMoa0900212
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
10.1016/J.YURO.2012.07.007
Abiraterone and Increased Survival in Metastatic Prostate Cancer: de Bono JS, for the COU-AA-301 Investigators (Inst of Cancer Res and Royal Marsden Hosp, Sutton, Surrey, UK; et al) N Engl J Med 364:1995-2005, 2011 §
G. Andriole (2012)
10.1056/NEJMOA064320
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
10.1016/S0140-6736(06)69446-4
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
G. Demetri (2006)
10.1093/JNCI/82.4.323
Is dose normalization to weight or body surface area useful in adults?
L. Grochow (1990)
10.1177/106002809302701202
Bioequivalence of Two Methotrexate Formulations in Psoriatic and Cancer Patients
M. Teresi (1993)
10.1016/S1470-2045(17)30339-X
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
A. Shaw (2017)
10.1200/JCO.2016.72.1316
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
R. Chen (2017)
Concomitant chemoradiotherapy versus induction docetaxel
A Paccagnella
A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (every 4 weeks) dosing schedule across multiple tumor types
X Zhao
10.1093/annonc/mdy181
Safety and dose modification for patients receiving niraparib
J. Berek (2018)
10.1038/clpt.2008.247
Novel Clinical Trial Designs for Innovative Therapies
J. Schellens (2009)
10.1093/ANNONC/MDH349
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
J. Tabernero (2004)
10.1016/S0140-6736(16)32453-9
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
J. Bruix (2017)
Population pharmacokinetics of doxorubicin, F Meriggi and A Zaniboni journals.sagepub.com/home/tam 11 etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
G Freyer (2000)
10.1056/NEJMoa1503093
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
10.1056/NEJMOA040720
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
I. Tannock (2004)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)



Semantic Scholar Logo Some data provided by SemanticScholar